In an independent cohort of patients with renal cell carcinoma who received bevacizumab monotherapy, we found no significant difference in baseline levels of total VEGF between patients who had progressing disease and those who had stable or regressing disease (Fig. 8f). Here, VEGFA is linked to hereditary clear cell renal cell carcinoma.